BioCentury
ARTICLE | Preclinical News

IL-11 receptor inhibition tied to osteosarcoma

July 13, 2017 1:41 AM UTC

In a paper published in Proceedings of the National Academy of Sciences, researchers showed that targeting the alpha subunit of the IL-11 receptor (IL-11R) with the bone metastasis-targeting peptidomimetic BMTP-11 reduces metastases and tumor growth. The team suggested that targeting the receptor could be used to treat high-risk osteosarcoma.

Spokesperson Vincent Anzalone told BioCentury that Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) has rights to BMTP-11, but does not currently plan to develop it further. The company obtained its rights in 2012 via its acquisition of Alvos Therapeutics Inc. (see BioCentury, Dec. 24, 2012)...